生长与治愈的平衡：儿童皮肤肿瘤与脉管畸形治疗的特殊性考量

doi:10.35541/cjd.20250178

中华皮肤科杂志 ›› 2025, Vol. 58 ›› Issue (10): 914-923.doi: 10.35541/cjd.20250178

• 专题笔谈·儿童皮肤病 • 上一篇下一篇

生长与治愈的平衡：儿童皮肤肿瘤与脉管畸形治疗的特殊性考量

李丽张斌徐教生孙娟陈云刘马琳

国家儿童医学中心首都医科大学附属北京儿童医院皮肤科儿科重大疾病研究教育部重点实验室，北京 100045

收稿日期:2025-04-03 修回日期:2025-07-15 发布日期:2025-09-30
通讯作者: 马琳 E-mail:bch_maleen@aliyun.com
基金资助:
北京市自然科学基金资助项目（7232054）；北京市医院管理中心“登峰”人才培养计划（DFL20241201）

Balancing growth and healing: special considerations in the treatment of pediatric skin tumors and vascular malformations

Li Li, Zhang Bin, Xu Jiaosheng, Sun Juan, Chen Yunliu, Ma Lin

Department of Dermatology, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing 100045, China

Received:2025-04-03 Revised:2025-07-15 Published:2025-09-30
Contact: Ma Lin E-mail:bch_maleen@aliyun.com
Supported by:
Beijing Natural Science Foundation （7232054）; Beijing Hospitals Authority′s Ascent Plan （DFL20241201）

摘要/Abstract

摘要： 【摘要】本文综述儿童皮肤肿瘤与脉管畸形的诊疗现状及研究进展，重点探讨血管瘤、脉管畸形、组织细胞增生症、肥大细胞增生症及蕈样肉芽肿的发病机制、临床表现、诊断及治疗选择。基于对儿童皮肤肿瘤独特的生长及消退模式的进一步认识，治疗策略逐渐优化。但儿童皮肤肿瘤治疗仍面临诸多挑战，未来研究需聚焦于建立儿童专属分子诊疗体系，并通过整合精准医学与个体化策略，优化患儿预后及生存质量。

关键词: 皮肤肿瘤, 儿童, 血管瘤, 脉管畸形, 组织细胞增生症, 肥大细胞增生症, 皮肤, 蕈样肉芽肿, 临床特征, 治疗

Abstract: 【Abstract】 This article summarizes the current status and research advances in the diagnosis and treatment of pediatric skin tumors and vascular malformations, with particular emphasis on the pathogenesis, clinical manifestations, diagnostic approaches, and therapeutic options for hemangiomas, vascular malformations, histiocytosis, mastocytosis, and mycosis fungoides. With the enhanced understanding of distinctive growth and regression patterns of pediatric skin tumors, therapeutic strategies have been progressively optimized. However, significant challenges persist in managing pediatric skin neoplasms. Future investigations should prioritize the establishment of pediatric-specific molecular diagnostic and therapeutic systems, and integrate precision medicine with individualized strategies, so as to improve clinical outcomes and quality of life in affected children.

Key words: Skin neoplasms, Child, Hemangioma, Vascular malformations, Histiocytosis, Mastocytosis, cutaneous, Mycosis fungoides, Clinical characteristics, Treatment

李丽张斌徐教生孙娟陈云刘马琳. 生长与治愈的平衡：儿童皮肤肿瘤与脉管畸形治疗的特殊性考量[J]. 中华皮肤科杂志, 2025,58(10):914-923. doi:10.35541/cjd.20250178

Li Li, Zhang Bin, Xu Jiaosheng, Sun Juan, Chen Yunliu, Ma Lin. Balancing growth and healing: special considerations in the treatment of pediatric skin tumors and vascular malformations[J]. Chinese Journal of Dermatology, 2025, 58(10): 914-923.doi:10.35541/cjd.20250178

参考文献 92

［1］	Narsinh KH, Gautam A, Baker A, et al. Vascular anomalies: classification and management［J］. Handb Clin Neurol, 2021,176:345⁃360. doi: 10.1016/B978⁃0⁃444⁃64034⁃5.00003⁃1.
［2］	Li J, Chen Q, Ni S, et al. CENPF may act as a novel marker and highlight the influence of pericyte in infantile hemangioma［J］. Angiology, 2024:33197241262373. doi: 10.1177/000331972412 62373.
［3］	de Jong S, Itinteang T, Withers AH, et al. Does hypoxia play a role in infantile hemangioma?［J］. Arch Dermatol Res, 2016,308（4）:219⁃227. doi: 10.1007/s00403⁃016⁃1635⁃x.
［4］	Rodríguez Bandera AI, Sebaratnam DF, Wargon O, et al. Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment［J］. J Am Acad Dermatol, 2021,85（6）:1379⁃1392. doi: 10.1016/j.jaad.2021.08.019.
［5］	Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex［J］. Arch Dermatol, 2002,138（12）:1567⁃1576. doi: 10.1001/archderm.138.12.1567.
［6］	Luu M, Frieden IJ. Haemangioma: clinical course, complications and management［J］. Br J Dermatol, 2013,169（1）:20⁃30. doi: 10.1111/bjd.12436.
［7］	Léauté⁃Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma［J］. Lancet, 2017,390（10089）:85⁃94. doi: 10.1016/S0140⁃6736（16）00645⁃0.
［8］	中华医学会整形外科分会血管瘤脉管畸形学组. 血管瘤与脉管畸形诊疗指南（2024版）［J］. 组织工程与重建外科, 2024,20（1）:1⁃50.
［9］	Sebaratnam DF, Rodríguez Bandera AL, Wong LF, et al. Infantile hemangioma. Part 2: management［J］. J Am Acad Dermatol, 2021,85（6）:1395⁃1404. doi: 10.1016/j.jaad.2021.08. 020.
［10］	郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）［J］. 中国口腔颌面外科杂志, 2022,20（04）:313⁃319. doi: 10.19438/j.cjoms.2022.04.001.
［11］	中华医学会皮肤性病学分会儿童学组, 中华医学会儿科学分会皮肤性病学组, 中国医师协会皮肤科医师分会儿童皮肤病专业委员会, 等. β受体阻滞剂治疗婴儿血管瘤中国专家共识［J］. 中华皮肤科杂志, 2020,53（7）:493⁃500. doi: 10.35541/cjd.20200302.
［12］	Léauté⁃Labrèze C, Frieden I, Delarue A. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate［J］. Pediatr Dermatol, 2023,40（2）:261⁃264. doi: 10.1111/pde.15198.
［13］	Ji Y, Chen S, Yang K, et al. Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial［J］. JAMA Otolaryngol Head Neck Surg, 2021,147（7）:599⁃607. doi: 10.1001/jamaoto.2021.0454.
［14］	阿替洛尔治疗婴幼儿血管瘤专家共识小组. 口服阿替洛尔治疗婴幼儿血管瘤的中国专家共识（2023年版）［J］. 临床小儿外科杂志, 2023,22（4）:301⁃306. doi: 10.3760/cma.j.cn101785⁃202207052⁃001.
［15］	Boull C, Maguiness SM. Congenital hemangiomas［J］. Semin Cutan Med Surg, 2016,35（3）:124⁃127. doi: 10.12788/j.sder.2016. 045.
［16］	Qiu T, Zhang Z, Zhou J, et al. Clinical features of rapid involuting congenital hemangioma: a prospective study［J］. J Am Acad Dermatol, 2024,90（4）:870⁃872. doi: 10.1016/j.jaad.2023. 12.036.
［17］	Weitz NA, Lauren CT, Starc TJ, et al. Congenital cutaneous hemangioma causing cardiac failure: a case report and review of the literature［J］. Pediatr Dermatol, 2013,30（6）:e180⁃190. doi: 10.1111/j.1525⁃1470.2012.01875.x.
［18］	Putra J, Gupta A. Kaposiform haemangioendothelioma: a review with emphasis on histological differential diagnosis［J］. Pathology, 2017,49（4）:356⁃362. doi: 10.1016/j.pathol.2017. 03.001.
［19］	Lim YH, Bacchiocchi A, Qiu J, et al. GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation［J］. Am J Hum Genet, 2016,99（2）:443⁃450. doi: 10.1016/j.ajhg.2016.06.010.
［20］	Ten Broek RW, Koelsche C, Eijkelenboom A, et al. Kaposiform hemangioendothelioma and tufted angioma ⁃ （epi）genetic analysis including genome⁃wide methylation profiling［J］. Ann Diagn Pathol, 2020,44:151434. doi: 10.1016/j.anndiagpath.2019. 151434.
［21］	Wang Y, Kong L, Sun B, et al. Sirolimus for Kaposiform hemangioendothelioma with Kasabach⁃Merritt phenomenon in two infants［J］. J Craniofac Surg, 2020,31（4）:1074⁃1077. doi: 10.1097/SCS.0000000000006301.
［22］	Tobe J, Shum D, Somers GR, et al. Port⁃wine stain⁃like presentation of a tufted angioma on the face［J］. Pediatr Dermatol, 2016,33（2）:e166⁃167. doi: 10.1111/pde.12805.
［23］	Yao W, Li KL, Qin ZP, et al. Standards of care for Kasabach⁃Merritt phenomenon in China［J］. World J Pediatr, 2021,17（2）:123⁃130. doi: 10.1007/s12519⁃020⁃00379⁃9.
［24］	Mahajan P, Margolin J, Iacobas I. Kasabach⁃Merritt phenomenon: classic presentation and management options［J］. Clin Med Insights Blood Disord, 2017,10:1179545X17699849. doi: 10.1177/1179545X17699849.
［25］	Johnson AB, Richter GT. Vascular anomalies［J］. Clin Perinatol, 2018,45（4）:737⁃749. doi: 10.1016/j.clp.2018.07.010.
［26］	Zhou J, Lan Y, Qiu T, et al. Efficacy and safety of high⁃vs low⁃dose sirolimus in patients with Kaposiform hemangioendothelioma: a randomized clinical trial［J］. J Am Acad Dermatol, 2025,93（1）:124⁃131. doi: 10.1016/j.jaad.2025.03.023.
［27］	Ji Y, Chen S, Zhou J, et al. Sirolimus plus prednisolone vs sirolimus monotherapy for Kaposiform hemangioendothelioma: a randomized clinical trial［J］. Blood, 2022,139（11）:1619⁃1630. doi: 10.1182/blood.2021014027.
［28］	Liu YX, Zhang J, Nie XL, et al. The effect of topical sirolimus on superficial Kaposiform haemangioendothelioma［J］. Australas J Dermatol, 2021,62（2）:e329⁃e331. doi: 10.1111/ajd.13499.
［29］	徐教生, 刘笑宇, 孙玉娟, 等. 外用卡替洛尔成功治疗儿童丛状血管瘤和化脓性肉芽肿［J］. 中华皮肤科杂志, 2015,48（12）:887⁃888. doi: 10.3760/cma.j.issn.0412⁃4030.2015.12.017.
［30］	Wei L, Li L, Xu Z, et al. Comparison of effectiveness of two different doses of propranolol on Kaposiform hemangioendothelioma［J］. Front Pediatr, 2022,10:760401. doi: 10.3389/fped.2022. 760401.
［31］	Yu L, Wei L, Ma L, et al. First report of oral atenolol for treatment of Kaposiform hemangioendothelioma, a viable alternative to propranolol［J］. J Dermatol, 2023,50（4）:e123⁃e124. doi: 10.1111/1346⁃8138.16657.
［32］	张斌, 何瑞, 宋俐, 等. 儿童复杂脉管畸形的分子诊断和靶向治疗的研究进展［J］. 中华预防医学杂志, 2023,57（9）:1481⁃1488. doi: 10.3760/cma.j.cn112150⁃20220930⁃00940.
［33］	何瑞, 马琳, 徐子刚, 等. GNAQ/ GNA11相关毛细血管畸形疾病谱的研究进展［J］. 中华预防医学杂志, 2025,59（2）:247⁃253. doi: 10.3760/cma.j.cn112150⁃20240728⁃00605.
［34］	Zhang B, He R, Xu Z, et al. Somatic mutation spectrum of a Chinese cohort of pediatrics with vascular malformations［J］. Orphanet J Rare Dis, 2023,18（1）:261. doi: 10.1186/s13023⁃023⁃02860⁃w.
［35］	Zhang B, He R, Wu R, et al. Somatic GNA11/GNAQ variants in a cohort of Chinese children with phakomatosis pigmentovascularis［J］. Pediatr Investig, 2024,8（2）:117⁃125. doi: 10.1002/ped4. 12424.
［36］	Parker V, Keppler⁃Noreuil KM, Faivre L, et al. Safety and efficacy of low⁃dose sirolimus in the PIK3CA⁃related overgrowth spectrum［J］. Genet Med, 2019,21（5）:1189⁃1198. doi: 10.1038/s41436⁃018⁃0297⁃9.
［37］	He R, Yin J, Zhang N, et al. Diagnosis and oral sirolimus treatment of fibro⁃adipose vascular anomaly in pediatric patients: a case series and comprehensive review［J］. Paediatr Drugs, 2025,27（4）:417⁃426. doi: 10.1007/s40272⁃025⁃00686⁃6.
［38］	张斌, 李丽, 尉莉, 等. 口服西罗莫司治疗儿童复杂性静脉畸形的效果和安全性：一项单中心前瞻性研究［J］. 中华整形外科杂志, 2020,36（5）:477⁃486. doi: 10.3760/cma.j.cn114453⁃20200315⁃00152.
［39］	Venot Q, Blanc T, Rabia SH, et al. Targeted therapy in patients with PIK3CA⁃related overgrowth syndrome［J］. Nature, 2018,558（7711）:540⁃546. doi: 10.1038/s41586⁃018⁃0217⁃9.
［40］	Biesecker LG, Edwards M, O'Donnell S, et al. Clinical report: one year of treatment of Proteus syndrome with miransertib （ARQ 092）［J］. Cold Spring Harb Mol Case Stud, 2020,6（1）doi: 10.1101/mcs.a004549.
［41］	Luder CM, Nordmann TM, Ramelyte E, et al. Histiocytosis ⁃ cutaneous manifestations of hematopoietic neoplasm and non⁃neoplastic histiocytic proliferations［J］. J Eur Acad Dermatol Venereol, 2018,32（6）:926⁃934. doi: 10.1111/jdv.14794.
［42］	Xu J, Ma H, Yao X, et al. Frequent detection of genetic aberrations reveals novel pathogenesis and treatment modalities in systemic juvenile xanthogranuloma［J］. Pediatr Investig, 2023,7（3）:212⁃215. doi: 10.1002/ped4.12398.
［43］	Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage⁃dendritic cell lineages［J］. Blood, 2016,127（22）:2672⁃2681. doi: 10.1182/blood⁃2016⁃01⁃690636.
［44］	McClain K, Weiss RA. Viruses and Langerhans cell histiocytosis: is there a link?［J］. Br J Cancer Suppl, 1994,23:S34⁃36.
［45］	Karpas A, Worman C, Arno J, et al. Sinus histiocytosis with massive lymphadenopathy: virological, immunological and morphological studies［J］. Br J Haematol, 1980,45（2）:195⁃200. doi: 10.1111/j.1365⁃2141.1980.tb07138.x.
［46］	Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance［J］. Br J Cancer Suppl, 1994,23:S29⁃33.
［47］	Mały E, Przyborska M, Rybczyńska A, et al. Juvenile xanthogranuloma with clonal proliferation in the bone marrow［J］. J Pediatr Hematol Oncol, 2012,34（3）:222⁃225. doi: 10. 1097/MPH.0b013e31823321ca.
［48］	Emile JF, Cohen⁃Aubart F, Collin M, et al. Histiocytosis［J］. Lancet, 2021,398（10295）:157⁃170. doi: 10.1016/S0140⁃6736（21）00311⁃1.
［49］	Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non⁃Langerhans cell histiocytoses［J］. Pediatr Blood Cancer, 2005,45（3）:256⁃264. doi: 10.1002/pbc.20246.
［50］	El Demellawy D, Young JL, de Nanassy J, et al. Langerhans cell histiocytosis: a comprehensive review［J］. Pathology, 2015,47（4）:294⁃301. doi: 10.1097/PAT.0000000000000256.
［51］	Xu J, Huang X, Wen Y, et al. Systemic juvenile xanthogranuloma has a higher frequency of ALK translocations than BRAFV600E mutations［J］. J Am Acad Dermatol, 2023,88（3）:656⁃659. doi: 10.1016/j.jaad.2020.08.053.
［52］	Xu J, Yao X, Wen Y, et al. Alectinib in the treatment of systemic juvenile xanthogranuloma of infancy with ALK translocation［J］. JAMA Dermatol, 2023,159（12）:1399⁃1401. doi: 10.1001/jamadermatol.2023.4027.
［53］	Lange M, Hartmann K, Carter MC, et al. Molecular background, clinical features and management of pediatric mastocytosis: status 2021［J］. Int J Mol Sci, 2021,22（5）:2586. doi: 10.3390/ijms22052586.
［54］	Garcia⁃Montero AC, Jara⁃Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis （REMA） in a series of 113 patients［J］. Blood, 2006,108（7）:2366⁃2372. doi: 10.1182/blood⁃2006⁃04⁃015545.
［55］	Bibi S, Langenfeld F, Jeanningros S, et al. Molecular defects in mastocytosis: KIT and beyond KIT［J］. Immunol Allergy Clin North Am, 2014,34（2）:239⁃262. doi: 10.1016/j.iac.2014.01.009.
［56］	Arock M, Sotlar K, Akin C, et al. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis［J］. Leukemia, 2015,29（6）:1223⁃1232. doi: 10.1038/leu.2015.24.
［57］	Valent P, Sotlar K, Horny HP, et al. World Health Organization classification and diagnosis of mastocytosis: update 2023 and future perspectives［J］. Immunol Allergy Clin North Am, 2023,43（4）:627⁃649. doi: 10.1016/j.iac.2023.04.011.
［58］	Lange M, Zawadzka A, Schrörs S, et al. The role of serum tryptase in the diagnosis and monitoring of pediatric mastocytosis: a single⁃center experience［J］. Postepy Dermatol Alergol, 2017,34（4）:306⁃312. doi: 10.5114/ada.2017.69308.
［59］	Carter MC, Bai Y, Ruiz⁃Esteves KN, et al. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease［J］. Br J Haematol, 2018,183（5）:775⁃782. doi: 10.1111/bjh.15624.
［60］	Czarny J, Żuk M, Zawrocki A, et al. New approach to paediatric mastocytosis: implications of KIT D816V mutation detection in peripheral blood［J］. Acta Derm Venereol, 2020,100（10）:adv00149. doi: 10.2340/00015555⁃3504.
［61］	Jendoubi F, Gaudenzio N, Gallini A, et al. Omalizumab in the treatment of adult patients with mastocytosis: a systematic review［J］. Clin Exp Allergy, 2020,50（6）:654⁃661. doi: 10.1111/cea.13592.
［62］	Hughes J, Olynyc T, Chapdelaine H, et al. Effective management of severe cutaneous mastocytosis in young children with omalizumab （Xolair®）［J］. Clin Exp Dermatol, 2018,43（5）:573⁃576. doi: 10.1111/ced.13408.
［63］	Bossi G, Brazzelli V, De Amici M, et al. Successful treatment with omalizumab of a child affected by systemic mastocytosis: clinical and biological implications［J］. Ital J Pediatr, 2023,49（1）:6. doi: 10.1186/s13052⁃022⁃01402⁃7.
［64］	Heide R, Beishuizen A, De Groot H, et al. Mastocytosis in children: a protocol for management［J］. Pediatr Dermatol, 2008,25（4）:493⁃500. doi: 10.1111/j.1525⁃1470.2008.00738.x.
［65］	Brazzelli V, Grassi S, Merante S, et al. Narrow⁃band UVB phototherapy and psoralen⁃ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients［J］. Photodermatol Photoimmunol Photomed, 2016,32（5⁃6）:238⁃246. doi: 10.1111/phpp.12248.
［66］	Brazzelli V, Bossi G, Bonelli A, et al. A case of pediatric indolent systemic mastocytosis: the role of UVB⁃NB phototherapy in the treatment of cutaneous lesions［J］. Photodermatol Photoimmunol Photomed, 2023,39（5）:540⁃542. doi: 10.1111/phpp.12894.
［67］	Mashiah J, Harel A, Bodemer C, et al. Topical pimecrolimus for paediatric cutaneous mastocytosis［J］. Clin Exp Dermatol, 2018,43（5）:559⁃565. doi: 10.1111/ced.13391.
［68］	Morren MA, Hoppé A, Renard M, et al. Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis［J］. J Pediatr, 2013,162（1）:205⁃207. doi: 10.1016/j.jpeds.2012.08.035.
［69］	Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2⁃year⁃old boy carrying a somatic KIT mutation［J］. Blood, 2008,112（5）:1655⁃1657. doi: 10.1182/blood⁃2008⁃03⁃147785.
［70］	van Anrooij B, Oude Elberink J, Span L, et al. Midostaurin in patients with indolent systemic mastocytosis: an open⁃label phase 2 trial［J］. J Allergy Clin Immunol, 2018,142（3）:1006⁃1008.e7. doi: 10.1016/j.jaci.2018.06.003.
［71］	Farrukh F, Gangat N, Shah MV, et al. Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo clinic experience［J］. Am J Hematol, 2022,97（4）:E138⁃E140. doi: 10.1002/ajh.26464.
［72］	Gotlib J, Reiter A, Radia DH, et al. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial［J］. Nat Med, 2021,27（12）:2192⁃2199. doi: 10.1038/s41591⁃021⁃01539⁃8.
［73］	Gotlib J, Castells M, Elberink HO, et al. Avapritinib versus placebo in indolent systemic mastocytosis［J］. NEJM Evid, 2023,2（6）:EVIDoa2200339. doi: 10.1056/EVIDoa2200339.
［74］	Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia［J］. Pediatr Blood Cancer, 2012,59（5）:840⁃845. doi: 10.1002/pbc.24121.
［75］	Voelker D, Bednarski JJ, Nieman E, et al. Hematopoietic KIT D816Y mutation presenting as in utero aggressive systemic mastocytosis with response to midostaurin［J］. J Allergy Clin Immunol Pract, 2023,11（4）:1323⁃1325.e1. doi: 10.1016/j.jaip.2022.12.016.
［76］	Hodak E, Lapidoth M, Kohn K, et al. Mycosis fungoides: HLA classⅡ associations among Ashkenazi and non⁃Ashkenazi Jewish patients［J］. Br J Dermatol, 2001,145（6）:974⁃980. doi: 10.1046/j.1365⁃2133.2001.04496.x.
［77］	Hodak E, Klein T, Gabay B, et al. Familial mycosis fungoides: report of 6 kindreds and a study of the HLA system［J］. J Am Acad Dermatol, 2005,52（3 Pt 1）:393⁃402. doi: 10.1016/j.jaad.2003.12.052.
［78］	Reiter O, Ben Amitai D, Amitay⁃Laish I, et al. Pediatric mycosis fungoides: a study of the human leukocyte antigen system among Israeli Jewish patients［J］. Arch Dermatol Res, 2017,309（10）:851⁃856. doi: 10.1007/s00403⁃017⁃1783⁃7.
［79］	Welfringer⁃Morin A, Barroil M, Fraitag S, et al. Clinical features, histological characteristics, and disease outcomes of mycosis fungoides in children and adolescents: a nationwide multicentre cohort of 46 patients［J］. Dermatology, 2023,239（1）:132⁃139. doi: 10.1159/000526788.
［80］	Brazzelli V, Bernacca C, Segal A, et al. Photo⁃photochemotherapy in juvenile⁃onset mycosis fungoides: a retrospective study on 9 patients［J］. J Pediatr Hematol Oncol, 2019,41（1）:34⁃37. doi: 10.1097/MPH.0000000000001277.
［81］	Hodak E, Amitay⁃Laish I, Feinmesser M, et al. Juvenile mycosis fungoides: cutaneous T⁃cell lymphoma with frequent follicular involvement［J］. J Am Acad Dermatol, 2014,70（6）:993⁃1001. doi: 10.1016/j.jaad.2013.12.029.
［82］	Pehlivan Ulutas G, Atci T, Baykal C. Comparison of pediatric⁃ and adult⁃onset mycosis fungoides patients in terms of clinical features and prognosis in a large series［J］. J Cutan Med Surg, 2025,29（3）:243⁃249. doi: 10.1177/12034754241302822.
［83］	Wain EM, Orchard GE, Whittaker SJ, et al. Outcome in 34 patients with juvenile⁃onset mycosis fungoides: a clinical, immunophenotypic, and molecular study［J］. Cancer, 2003,98（10）:2282⁃2290. doi: 10.1002/cncr.11780.
［84］	Nanda A, AlSaleh QA, Al⁃Ajmi H, et al. Mycosis fungoides in Arab children and adolescents: a report of 36 patients from Kuwait［J］. Pediatr Dermatol, 2010,27（6）:607⁃613. doi: 10. 1111/j.1525⁃1470.2010.01129.x.
［85］	Cervini AB, Torres⁃Huamani AN, Sanchez⁃La⁃Rosa C, et al. Mycosis fungoides: experience in a pediatric hospital［J］. Actas Dermosifiliogr, 2017,108（6）:564⁃570. doi: 10.1016/j.ad.2017. 01.008.
［86］	Heng YK, Koh MJ, Giam YC, et al. Pediatric mycosis fungoides in Singapore: a series of 46 children［J］. Pediatr Dermatol, 2014,31（4）:477⁃482. doi: 10.1111/pde.12352.
［87］	Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides［J］. J Am Acad Dermatol, 2005,53（6）:1053⁃1063. doi: 10.1016/j.jaad.2005.08.057.
［88］	Chen Y, Xu J, Qiu L, et al. Hypopigmented mycosis fungoides: a clinical and histopathology analysis in 9 children［J］. Am J Dermatopathol, 2021,43（4）:259⁃265. doi: 10.1097/DAD.000000 0000001723.
［89］	Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience［J］. Arch Dermatol, 2003,139（2）:165⁃173. doi: 10.1001/archderm.139.2.165.
［90］	Valencia Ocampo OJ, Julio L, Zapata V, et al. Mycosis fungoides in children and adolescents: a series of 23 cases［J］. Actas Dermosifiliogr （Engl Ed）, 2020,111（2）:149⁃156. doi: 10.1016/j.ad.2019.04.004.
［91］	Kothari R, Szepietowski JC, Bagot M, et al. Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management［J］. Int J Dermatol, 2022,61（12）:1458⁃1466. doi: 10.1111/ijd.16098.
［92］	Yazganoglu KD, Topkarci Z, Buyukbabani N, et al. Childhood mycosis fungoides: a report of 20 cases from Turkey［J］. J Eur Acad Dermatol Venereol, 2013,27（3）:295⁃300. doi: 10.1111/j.1468⁃3083.2011.04383.x.

[1]	周妙妮盛安琪傅丽芳金嵘许文尉晓冬许爱娥. 茶多酚抗氧化凝胶联合窄谱中波紫外线治疗白癜风的疗效及安全性单中心随机对照试验[J]. 中华皮肤科杂志, 2025, 58(9): 834-838.
[2]	戴叶芹宋秀祖. 毛囊及毛囊细胞移植在白癜风治疗中的应用进展[J]. 中华皮肤科杂志, 2025, 58(9): 882-885.
[3]	徐中奕邢小雪董雅琦张成锋项蕾红. 上海市某三甲医院黄褐斑患者254例临床特征及疗效的回顾性分析[J]. 中华皮肤科杂志, 2025, 58(9): 808-815.
[4]	王雯竹杨荷丹刘蕴瑶孙小洁张晓丽李秀珍谭思齐徐浩翔杨寅林彤. [开放获取] miR-25-5p靶向RAB11B参与调控皮肤色素沉着的机制研究[J]. 中华皮肤科杂志, 2025, 58(9): 816-824.
[5]	王琛丁玥岑董雅琦张成锋项蕾红徐中奕. 真皮获得性斑状色素沉着诊疗进展[J]. 中华皮肤科杂志, 2025, 58(9): 873-877.
[6]	姜子琪钟菊丹陈廷巧陈瑾. 黄褐斑发病机制及治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 868-872.
[7]	钟洁敏李薇张淑娟杨艳薛如君李欣怡柯娅楠陈晓吟陈荃. 纳米微针与超声波导入氨甲环酸治疗黄褐斑的疗效与安全性比较：一项随机对照研究[J]. 中华皮肤科杂志, 2025, 58(9): 829-833.
[8]	张成锋金尚霖. 黄褐斑发病机制与临床对策的新认识[J]. 中华皮肤科杂志, 2025, 58(9): 797-800.
[9]	谭薇白云陈裕充徐明圆刘业强. 国内首报CRTC1::TRIM11融合皮肤肿瘤1例[J]. 中华皮肤科杂志, 2025, 58(9): 825-828.
[10]	朱婷婷, 李蔚然潘召兵刘昊唐先发朱才红黄鹤群段大威张若晨陈小建汪洋薛倩张菊锐杨丽婧张学军, 黄贺, 张博, . 巴瑞替尼联合芦可替尼乳膏治疗6例进展期非节段型白癜风患者的疗效观察[J]. 中华皮肤科杂志, 2025, 58(9): 856-859.
[11]	田翠翠陈浩. 皮肤T细胞淋巴瘤瘙痒发病机制研究进展[J]. 中华皮肤科杂志, 2025, 58(9): 890-892.
[12]	姜倩胡彬陈瑶陈柳青. 儿童面部获得性色素沉着斑131例临床及影像学特征回顾分析[J]. 中华皮肤科杂志, 2025, 58(9): 843-847.
[13]	罗帅寒天龙海陆前进. 2024年系统性红斑狼疮研究新进展[J]. 中华皮肤科杂志, 2025, 58(8): 777-780.
[14]	中国医师协会皮肤科医师分会痤疮学组中国研究型医院学会皮肤科学专业委员会中国中西医结合学会皮肤性病专业委员会痤疮学组. [开放获取] 寻常痤疮临床严重度分级及疗效评价中国专家共识（2025版）[J]. 中华皮肤科杂志, 2025, 58(8): 709-714.
[15]	薛珂陈佳李斌. 系统性红斑狼疮靶向治疗研究进展[J]. 中华皮肤科杂志, 2025, 58(8): 781-784.

生长与治愈的平衡：儿童皮肤肿瘤与脉管畸形治疗的特殊性考量

Balancing growth and healing: special considerations in the treatment of pediatric skin tumors and vascular malformations

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 92

相关文章 15

Metrics

本文评价

推荐阅读 10